{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:50:15Z","timestamp":1791528615195,"version":"4.3.4"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001445","name":"Alex's Lemonade Stand Foundation for Childhood Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001445","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000146","name":"Alberta Innovates - Technology Futures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000146","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.actbio.2024.08.053","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T11:43:51Z","timestamp":1725363831000},"page":"297-314","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Lipopolymer\/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9905-3097","authenticated-orcid":false,"given":"Aysha S.","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cezary","family":"Kucharski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3554-7247","authenticated-orcid":false,"given":"Remant","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5310-280X","authenticated-orcid":false,"given":"Daniel","family":"Nisakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9501-2272","authenticated-orcid":false,"given":"Ramea","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8974-7340","authenticated-orcid":false,"given":"Xiaoyan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Brandwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1118-4170","authenticated-orcid":false,"given":"Hasan","family":"Uluda\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2024.08.053_bib0001","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s13238-013-3057-2","article-title":"The evolving landscape in the therapy of acute myeloid leukemia","volume":"4","author":"Peloquin","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.actbio.2024.08.053_bib0002","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"New England J. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0003","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"New England J. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0004","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1182\/asheducation-2013.1.220","article-title":"FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?","volume":"2013","author":"Levis","year":"2013","journal-title":"Hematology."},{"key":"10.1016\/j.actbio.2024.08.053_bib0005","first-page":"1121","article-title":"Flt3 ligand stimulates\/costimulates the growth of myeloid stem\/progenitor cells","volume":"23","author":"Broxmeyer","year":"1995","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0006","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.4049\/jimmunol.157.7.2953","article-title":"The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta","volume":"157","author":"Veiby","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0007","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-4-36","article-title":"Current findings for recurring mutations in acute myeloid leukemia","volume":"4","author":"Takahashi","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4081\/oncol.2012.e8","article-title":"An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment","volume":"6","author":"Grafone","year":"2012","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.actbio.2024.08.053_bib0009","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2024.08.053_bib0010","first-page":"7233","article-title":"Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study","volume":"61","author":"Whitman","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0011","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.hoc.2011.09.018","article-title":"Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia","volume":"25","author":"Grimwade","year":"2011","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.actbio.2024.08.053_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0013","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00277-020-04186-0","article-title":"Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia","volume":"99","author":"Meg\u00edas-Vericat","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0014","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-Molecule Fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.actbio.2024.08.053_bib0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-021-00495-3","article-title":"FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm","volume":"11","author":"Daver","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.actbio.2024.08.053_bib0016","unstructured":"Cancer Facts & Figs. 2022 American cancer society N.D. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html (accessed January 16, 2023)."},{"key":"10.1016\/j.actbio.2024.08.053_bib0017","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2024.08.053_bib0018","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13045-020-00992-1","article-title":"Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia","volume":"13","author":"Gebru","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0019","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/cas.14274","article-title":"FLT3 mutations in acute myeloid leukemia: therapeutic paradigm beyond inhibitor development","volume":"111","author":"Kiyoi","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.actbio.2024.08.053_bib0020","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1182\/hematology.2019000058","article-title":"The growing landscape of FLT3 inhibition in AML","volume":"2019","author":"Smith","year":"2019","journal-title":"Hematology."},{"key":"10.1016\/j.actbio.2024.08.053_bib0021","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.actbio.2024.08.053_bib0022","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0023","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.actbio.2024.08.053_bib0024","doi-asserted-by":"crossref","DOI":"10.1039\/C7TB01833A","article-title":"Biomaterials for polynucleotide delivery to anchorage-independent cells","volume":"5","author":"Ansari","year":"2017","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.actbio.2024.08.053_bib0025","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/or.2021.8229","article-title":"Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K\/AKT and RhoA\/ROCK pathways in acute myeloid leukemia","volume":"47","author":"Liang","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.actbio.2024.08.053_bib0026","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jconrel.2022.05.043","article-title":"Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines","volume":"348","author":"Liu","year":"2022","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0027","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1080\/21655979.2022.2036903","article-title":"RAB27B inhibits proliferation and promotes apoptosis of leukemic cells via 3-Hydroxy butyrate dehydrogenase 2 (BDH2)","volume":"13","author":"Meng","year":"2022","journal-title":"Bioengineered."},{"key":"10.1016\/j.actbio.2024.08.053_bib0028","article-title":"LYPD3, a New biomarker and therapeutic target for acute myelogenous leukemia","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Genet."},{"key":"10.1016\/j.actbio.2024.08.053_bib0029","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3390\/biomedicines10051038","article-title":"Targeting TKI-activated NFKB2-MIF\/CXCLs-CXCR2 signaling pathways in FLT3 mutated acute myeloid leukemia reduced blast viability","volume":"10","author":"Cao","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.actbio.2024.08.053_bib0030","doi-asserted-by":"crossref","first-page":"5295","DOI":"10.1111\/jcmm.16539","article-title":"ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN\/PI3K\/AKT signalling pathway by combining with P53","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0031","doi-asserted-by":"crossref","first-page":"5413","DOI":"10.7150\/jca.60885","article-title":"PSD3 is an oncogene that promotes proliferation, migration, invasion, and G1\/S transition while inhibits apoptotic in papillary thyroid cancer","volume":"12","author":"Jin","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.actbio.2024.08.053_bib0032","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3892\/ol.2020.11718","article-title":"HLX affects cell cycle and proliferation in AML cells via the JAK\/STAT signaling pathway","volume":"20","author":"Zhu","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.actbio.2024.08.053_bib0033","doi-asserted-by":"crossref","first-page":"e207","DOI":"10.1097\/CAD.0000000000001188","article-title":"LINC00987 knockdown inhibits the progression of acute myeloid leukemia by suppressing IGF2BP2-mediated PA2G4 expression","volume":"33","author":"Liu","year":"2022","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.actbio.2024.08.053_bib0034","doi-asserted-by":"crossref","DOI":"10.1177\/1533033820942312","article-title":"PPM1D knockdown suppresses cell proliferation, promotes cell apoptosis, and activates p38 MAPK\/p53 signaling pathway in acute myeloid leukemia","volume":"19","author":"Li","year":"2020","journal-title":"Technol. Cancer Res. Treat."},{"key":"10.1016\/j.actbio.2024.08.053_bib0035","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2018.211201","article-title":"Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia","volume":"105","author":"Sharma","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2024.08.053_bib0036","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.3390\/ijms20235931","article-title":"IL-1\u03b2 induces SOCS2 expression in human dendritic cells","volume":"20","author":"Sarajlic","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2024.08.053_bib0037","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.3390\/molecules23123306","article-title":"23-Hydroxyursolic acid isolated from the stem bark of cussonia bancoensis induces apoptosis through fas\/caspase-8-dependent pathway in HL-60 Human promyelocytic leukemia cells","volume":"23","author":"Won","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.actbio.2024.08.053_bib0038","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.2147\/OTT.S162407","article-title":"Downregulation of PDIA3 inhibits proliferation and invasion of human acute myeloid leukemia cells","volume":"11","author":"Ye","year":"2018","journal-title":"Onco Targets. Ther."},{"key":"10.1016\/j.actbio.2024.08.053_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106198","article-title":"CircPAN3 contributes to drug resistance in acute myeloid leukemia through regulation of autophagy","volume":"85","author":"Shang","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0040","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.3390\/molecules23102564","article-title":"Systematic screening of commonly used commercial transfection reagents towards efficient transfection of single-stranded oligonucleotides","volume":"23","author":"Wang","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.actbio.2024.08.053_bib0041","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/mt.2013.210","article-title":"Discovery of siRNA lipid nanoparticles to transfect suspension leukemia cells and provide in vivo delivery capability","volume":"22","author":"He","year":"2014","journal-title":"Mol. Therapy"},{"key":"10.1016\/j.actbio.2024.08.053_bib0042","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.3390\/pharmaceutics13101681","article-title":"Development of siRNA-loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a novel and safe therapeutic approach for t(8;21) pediatric acute myeloid leukemia","volume":"13","author":"Connerty","year":"2021","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.actbio.2024.08.053_bib0043","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/cancers12102766","article-title":"Targeted inhibition of the NUP98-NSD1 fusion oncogene in acute myeloid leukemia","volume":"12","author":"Mohanty","year":"2020","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.actbio.2024.08.053_bib0044","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jconrel.2013.10.013","article-title":"Determination of key structure\u2013activity relationships in siRNA delivery with a mixed micelle system","volume":"172","author":"Omedes Pujol","year":"2013","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jinorgbio.2018.01.001","article-title":"Ruthenium dendrimers as carriers for anticancer siRNA","volume":"181","author":"Michlewska","year":"2018","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/j.actbio.2024.08.053_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2022.119646","article-title":"Effective RNAi in leukemia cells is enhanced by spermine-modified pullulan combined with desloratadine","volume":"292","author":"Wang","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.actbio.2024.08.053_bib0047","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.3390\/ijms23179791","article-title":"Co-formulation of amphiphilic cationic and anionic cyclodextrins forming nanoparticles for siRNA delivery in the treatment of acute myeloid Leukaemia","volume":"23","author":"Kont","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.actbio.2024.08.053_bib0048","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1021\/acs.molpharmaceut.6b01150","article-title":"Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy","volume":"14","author":"Guo","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.actbio.2024.08.053_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111583","article-title":"Efficient tumor-targeting delivery of siRNA via folate-receptor mediated biomimetic albumin nanoparticles enhanced by all-trans retinoic acid","volume":"119","author":"Wang","year":"2021","journal-title":"Mater. Sci. Eng.: C"},{"key":"10.1016\/j.actbio.2024.08.053_bib0050","doi-asserted-by":"crossref","first-page":"8658","DOI":"10.1039\/D0TB01177K","article-title":"A non-viral nano-delivery system targeting epigenetic methyltransferase EZH2 for precise acute myeloid leukemia therapy","volume":"8","author":"Kaundal","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.actbio.2024.08.053_bib0051","doi-asserted-by":"crossref","first-page":"25633","DOI":"10.1021\/acsami.0c06186","article-title":"Epigenetic regulation of bmi1 by ubiquitination and proteasomal degradation inhibit Bcl-2 in acute myeloid leukemia","volume":"12","author":"Kushwaha","year":"2020","journal-title":"ACS. Appl. Mater. Interfaces."},{"key":"10.1016\/j.actbio.2024.08.053_bib0052","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119651","article-title":"CD64-targeted HO-1 RNA interference enhances chemosensitivity in orthotopic model of acute myeloid leukemia and patient-derived bone marrow cells","volume":"230","author":"Yong","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2024.08.053_bib0053","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13045-022-01390-5","article-title":"Electrostatic anti-CD33-antibody\u2013protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia","volume":"15","author":"B\u00e4umer","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112609","article-title":"Novel nanocarriers for silencing anti-phagocytosis CD47 marker in acute myeloid leukemia cells","volume":"217","author":"Hassan","year":"2022","journal-title":"Colloids. Surf. B Biointerfaces."},{"key":"10.1016\/j.actbio.2024.08.053_bib0055","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2019.08.018","article-title":"siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers","volume":"310","author":"Valencia-Serna","year":"2019","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0056","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/jbm.a.36837","article-title":"Cholesterol grafted cationic lipopolymers: Potential siRNA carriers for selective chronic myeloid leukemia therapy","volume":"108","author":"Remant","year":"2020","journal-title":"J. Biomed. Mater. Res. a"},{"key":"10.1016\/j.actbio.2024.08.053_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044197","article-title":"Effective non-viral delivery of siRNA to acute myeloid leukemia cells with lipid-substituted polyethylenimines","volume":"7","author":"Landry","year":"2012","journal-title":"PLoS. One"},{"key":"10.1016\/j.actbio.2024.08.053_bib0058","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jconrel.2015.12.052","article-title":"Targeting CXCR4\/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia","volume":"224","author":"Landry","year":"2016","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0059","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.4161\/cc.3.8.1023","article-title":"Analysis of FDA approved anticancer drugs reveals the future of cancer therapy","volume":"3","author":"Blagosklonny","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1016\/j.actbio.2024.08.053_bib0060","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1200\/JCO.2011.37.6418","article-title":"Development of therapeutic combinations targeting major cancer signaling pathways","volume":"31","author":"Yap","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0061","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/03639045.2017.1313861","article-title":"Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems","volume":"43","author":"Babu","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.actbio.2024.08.053_bib0062","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jconrel.2014.09.001","article-title":"Nanocarrier mediated delivery of siRNA\/miRNA in combination with chemotherapeutic agents for cancer therapy: Current progress and advances","volume":"194","author":"Gandhi","year":"2014","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"10.1016\/j.actbio.2024.08.053_bib0064","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/mabi.201000402","article-title":"Impact of lipid substitution on assembly and delivery of siRNA by cationic polymers","volume":"11","author":"Aliabadi","year":"2011","journal-title":"Macromol. Biosci."},{"key":"10.1016\/j.actbio.2024.08.053_bib0065","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.jconrel.2013.05.014","article-title":"Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation","volume":"172","author":"Valencia-Serna","year":"2013","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0066","volume":"171","author":"Wu","year":"2022","journal-title":"Multiple gene knockdown strategies for investigating the properties of human leukemia stem cells and exploring new therapies"},{"key":"10.1016\/j.actbio.2024.08.053_bib0067","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jconrel.2024.02.018","article-title":"Lipopolymer mediated siRNA delivery targeting aberrant oncogenes for effective therapy of myeloid leukemia in preclinical animal models","volume":"367","author":"Ansari","year":"2024","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0251719","article-title":"Therapeutic delivery of siRNA with polymeric carriers to down-regulate STAT5A expression in high-risk B-cell acute lymphoblastic leukemia (B-ALL)","volume":"16","author":"Mohseni","year":"2021","journal-title":"PLoS. One"},{"key":"10.1016\/j.actbio.2024.08.053_bib0069","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.actbio.2022.06.030","article-title":"In Vitro cytotoxicity and cytokine production by lipid-substituted low molecular weight branched PEIs used for gene delivery","volume":"148","author":"Meenakshi Sundaram","year":"2022","journal-title":"Acta Biomater."},{"key":"10.1016\/j.actbio.2024.08.053_bib0070","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nmeth.2847","article-title":"Identification of small molecules that support human leukemia stem cell activity ex vivo","volume":"11","author":"Pabst","year":"2014","journal-title":"Nat. Methods"},{"key":"10.1016\/j.actbio.2024.08.053_bib0071","doi-asserted-by":"crossref","first-page":"W130","DOI":"10.1093\/nar\/gkh366","article-title":"siRNA Selection Server: an automated siRNA oligonucleotide prediction server","volume":"32","author":"Yuan","year":"2004","journal-title":"Nucleic. Acids. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0072","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2402740","article-title":"FLT3 mutations in acute myeloid leukemia cell lines","volume":"17","author":"Quentmeier","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.actbio.2024.08.053_bib0073","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2\u2212\u0394\u0394CT method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.actbio.2024.08.053_bib0074","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1182\/blood-2017-12-819508","article-title":"RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML","volume":"131","author":"Cucchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0075","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1182\/blood-2017-09-807438","article-title":"The impact of age, NPM1mut, and FLT3ITD allelic ratio in patients with acute myeloid leukemia","volume":"131","author":"Straube","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0076","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0077","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","article-title":"Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD","volume":"133","author":"Schlenk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0078","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA approval summary: gilteritinib for relapsed or refractory acute myeloid leukemia with a flt3 mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0079","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1158\/1535-7163.MCT-16-0876","article-title":"FLT3 inhibitors in acute myeloid leukemia: current status and future directions","volume":"16","author":"Larrosa-Garcia","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.actbio.2024.08.053_bib0080","doi-asserted-by":"crossref","DOI":"10.1182\/hem.V15.1.8155","article-title":"A landmark year for FDa-approved therapies for acute myeloid leukemia","volume":"15","author":"Abdel-Wahab","year":"2018","journal-title":"The Hematologist"},{"key":"10.1016\/j.actbio.2024.08.053_bib0081","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13045-019-0774-x","article-title":"Recent drug approvals for acute myeloid leukemia","volume":"12","author":"Lai","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0082","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J. National Comprehensive Cancer Network"},{"key":"10.1016\/j.actbio.2024.08.053_bib0083","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2022.100063","article-title":"siRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy","volume":"7","author":"Paul","year":"2022","journal-title":"OpenNano"},{"key":"10.1016\/j.actbio.2024.08.053_bib0084","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V70.5.1233.1233","article-title":"The HL-60 promyelocytic leukemia cell line: proliferation, differentiation, and cellular oncogene expression","volume":"70","author":"Collins","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0085","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0145-2126(97)00036-2","article-title":"Mutations of the RAS genes in childhood acute myeloid leukemia, myelodysplastic syndrome and juvenile chronic myelocytic leukemia","volume":"21","author":"Sheng","year":"1997","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0086","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood.V79.9.2378.2378","article-title":"Frequent mutations in the p53 gene in human myeloid leukemia cell lines","volume":"79","author":"Sugimoto","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0087","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.actbio.2024.08.053_bib0088","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1097-2765(03)00505-7","article-title":"The Structural basis for autoinhibition of FLT3 by the juxtamembrane domain","volume":"13","author":"Griffith","year":"2004","journal-title":"Mol. Cell"},{"key":"10.1016\/j.actbio.2024.08.053_bib0089","first-page":"1617","article-title":"Detailed analysis of FLT3 expression levels in acute myeloid leukemia","volume":"90","author":"Kuchenbauer","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.actbio.2024.08.053_bib0090","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2017.8232","article-title":"High expression of FLT3 is a risk factor in leukemia","author":"Cheng","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.actbio.2024.08.053_bib0091","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2024.08.053_bib0092","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.actbio.2024.08.053_bib0093","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0094","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.leukres.2005.07.015","article-title":"Inverse correlation between Flt3 and PU.1 expression in acute myeloblastic leukemias","volume":"30","author":"Inomata","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0095","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1038\/sj.onc.1210980","article-title":"The FLT3 inhibitor PKC412 exerts differential cell cycle effects on leukemic cells depending on the presence of FLT3 mutations","volume":"27","author":"Odgerel","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.actbio.2024.08.053_bib0096","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1182\/blood-2010-08-301796","article-title":"Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse","volume":"117","author":"Levis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0097","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.leukres.2009.10.001","article-title":"Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse","volume":"34","author":"Ravandi","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0098","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659253","article-title":"Escape from treatment; the different faces of leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"11","author":"van Gils","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0099","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1186\/1471-2407-13-378","article-title":"Combination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines","volume":"13","author":"Mokhtari","year":"2013","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.actbio.2024.08.053_bib0100","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J.Clin. Oncol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0101","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrc706","article-title":"Multidrug resistance in cancer: role of ATP\u2013dependent transporters","volume":"2","author":"Gottesman","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2024.08.053_bib0102","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jconrel.2009.09.004","article-title":"Nanoparticle-mediated combination chemotherapy and photodynamic therapy overcomes tumor drug resistance","volume":"141","author":"Khdair","year":"2010","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.actbio.2024.08.053_bib0103","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Mokhtari","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.actbio.2024.08.053_bib0104","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","article-title":"Effective drug combinations in breast, colon and pancreatic cancer cells","volume":"603","author":"Jaaks","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2024.08.053_bib0105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2012.01.008","article-title":"Nanoparticle-based combination therapy toward overcoming drug resistance in cancer","volume":"83","author":"Hu","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.actbio.2024.08.053_bib0106","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.colsurfb.2017.06.002","article-title":"Recent advances in mechanism-based chemotherapy drug-siRNA pairs in co-delivery systems for cancer: A review","volume":"157","author":"Wang","year":"2017","journal-title":"Colloids. Surf. B Biointerfaces."},{"key":"10.1016\/j.actbio.2024.08.053_bib0107","unstructured":"https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"10.1016\/j.actbio.2024.08.053_bib0108","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.leukres.2014.11.027","article-title":"Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy","volume":"39","author":"Erba","year":"2015","journal-title":"Leuk. Res."},{"key":"10.1016\/j.actbio.2024.08.053_bib0109","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3390\/biomedicines8080245","article-title":"Mechanisms underlying resistance to FLT3 inhibitors in acute myeloid leukemia","volume":"8","author":"Eguchi","year":"2020","journal-title":"Biomedicines."},{"key":"10.1016\/j.actbio.2024.08.053_bib0110","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3 -mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.actbio.2024.08.053_bib0111","doi-asserted-by":"crossref","first-page":"5327","DOI":"10.1038\/s41467-020-19119-8","article-title":"Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics","volume":"11","author":"Morita","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2024.08.053_bib0112","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/nm.4410","article-title":"Clonal evolution in leukemia","volume":"23","author":"Ferrando","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2024.08.053_bib0113","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2010-01-266742","article-title":"FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo","volume":"117","author":"Sato","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2024.08.053_bib0114","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2147\/OTT.S384293","article-title":"Therapeutic targeting of FLT3 in acute myeloid leukemia: current status and novel approaches","volume":"15","author":"Tecik","year":"2022","journal-title":"Onco Targets. Ther."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124005051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706124005051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T20:55:10Z","timestamp":1728939310000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706124005051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":114,"alternative-id":["S1742706124005051"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2024.08.053","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipopolymer\/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2024.08.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}